您搜索了: fondaparinux (马耳他语 - 英语)

ta ’ fondaparinux.
the fondaparinux dose (10 mg) in ro

fondaparinux sodium
arixtra 1.5 mg/ 0.3 ml solution for injection fondaparinux sodium

fondaparinux naqqas ed
d fondaparinux also significantly reduced the rate of adjudicated fatal pe [0 patients (0.0%) vs 5

fondaparinux 2. 5 mg
over 8,000 patients (hip fracture – 1,711, hip replacement – 5,829, major knee surgery – 1,367) were studied in controlled phase ii and iii clinical studies.

fondaparinux naqqas sinifikament
this study included acutely ill medical patients, aged ≥ 60 years, expected to require bed rest for at least four days, and hospitalized for congestive heart failure nyha class iii/ iv and/ or acute respiratory illness and/ or acute infectious or inflammatory disease.

fondaparinux 2. 5 mg tm
fondaparinux 2.5 mg once daily started 6-8 hours postoperatively was compared with enoxaparin 40 mg once daily started 12 hours before surgery, or 30 mg twice daily

fondaparinux għandu jintuża im
the duration of treatment should not exceed that evaluated during clinical trial (mean 7 days)

in vitro, fondaparinux jeħel od
in vitro, fondaparinux is highly and ro

m’hemmx antidotu għal fondaparinux
there is no known antidote to fondaparinux.

m’ hemmx antidotu għal fondaparinux.
is no known antidote to fondaparinux.

fondaparinux f’ doża ta ’ 5mg kuljum
fondaparinux should be used with caution at a daily dose of 5 mg in this population (see sections 4.2 and 5.2).

izda, l- użu ta ’ fondaparinux għandu
however, the use of fondaparinux should be m

to fondaparinux (ara sezzjoni 5. 2).
as renal function is generally decreasing with age, elderly patients may show reduced elimination and increased exposure of fondaparinux (see section 5.2).

fondaparinux hu intiż għal użu subkutanju biss.
fondaparinux is intended for subcutaneous use only.

0% (fondaparinux kontra l- kontroll). na
ut 1.2% vs 0% (fondaparinux vs. control).

fondaparinux ma jinattivax l- enżima li tikkawża
fondaparinux does not m

fondaparinux huwa intenzjonat għall-użu subkutanju biss.
fondaparinux is intended for subcutaneous use only.

arixtra fiha sustanza sintetika msemmija fondaparinux sodium.
arixtra contains a synthetic substance called fondaparinux sodium.

sensittività eċċessiva għal fondaparinux jew għal xi sustanzi mhux attivi
hypersensitivity to the active substance or to any of the excipients

sa 64- 77% ta ’ fondaparinux jitneħħa mill- kliewi
fondaparinux is excreted to 64 – 77% by the kidney as unchanged compound.